Platelet Lysate as Replacement for Fetal Bovine Serum in Mesenchymal Stromal Cell Cultures
暂无分享,去创建一个
[1] Ludwika Kreja,et al. GMP-Compliant Isolation and Expansion of Bone Marrow-Derived MSCs in the Closed, Automated Device Quantum Cell Expansion System , 2013, Cell transplantation.
[2] N. Brick. Autologous platelet-rich plasma for treating chronic wounds. , 2013, The American journal of nursing.
[3] O. Lindvall,et al. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls , 2013, The EMBO journal.
[4] R. Henschler,et al. Cultivation in human serum reduces adipose tissue-derived mesenchymal stromal cell adhesion to laminin and endothelium and reduces capillary entrapment. , 2013, Stem cells and development.
[5] H. Hoeksema,et al. The use of platelet-rich plasma in plastic surgery: a systematic review. , 2013, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.
[6] Gregor Bein,et al. Good manufacturing practice-compliant animal-free expansion of human bone marrow derived mesenchymal stroma cells in a closed hollow-fiber-based bioreactor. , 2013, Biochemical and biophysical research communications.
[7] C. Choong,et al. MSCs into adipogenic, chondrogenic, and osteogenic lineages identify markers and signaling pathways important in differentiation of growth of mesenchymal stem cells (MSCs): transcriptional profiling can , and FGF signaling is important for differentiation and β PDGF, TGF- , 2013 .
[8] Karen Bieback,et al. Expansion of Mesenchymal Stem/Stromal cells under xenogenic-free culture conditions. , 2013, Advances in biochemical engineering/biotechnology.
[9] C. Lange,et al. Platelet lysate suppresses the expression of lipocalin-type prostaglandin D2 synthase that positively controls adipogenic differentiation of human mesenchymal stromal cells. , 2012, Experimental cell research.
[10] Rachel M. Buchanan,et al. Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. , 2012, Biomaterials.
[11] M. Zenke,et al. Donor Age of Human Platelet Lysate Affects Proliferation and Differentiation of Mesenchymal Stem Cells , 2012, PloS one.
[12] A. Ignatius,et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components , 2012, Cytotherapy.
[13] N. Simunovic,et al. Efficacy of autologous platelet-rich plasma use for orthopaedic indications: a meta-analysis. , 2012, The Journal of bone and joint surgery. American volume.
[14] F. Locatelli,et al. Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine? , 2012, Bone Marrow Transplantation.
[15] L. Moretta,et al. Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T‐ and NK‐cell proliferation and function , 2011, European journal of immunology.
[16] M. Murray,et al. The effect of platelet concentrates on graft maturation and graft-bone interface healing in anterior cruciate ligament reconstruction in human patients: a systematic review of controlled trials. , 2011, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.
[17] D. Strunk,et al. Immunomodulative Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells Cultured in Human Platelet Lysate , 2011, Journal of Clinical Immunology.
[18] Arnold I Caplan,et al. The MSC: an injury drugstore. , 2011, Cell stem cell.
[19] A. Dietz,et al. Platelet Lysate Consisting of a Natural Repair Proteome Supports Human Mesenchymal Stem Cell Proliferation and Chromosomal Stability , 2011, Cell transplantation.
[20] S. Giannini,et al. Mesenchymal stem cells and platelet lysate in fibrin or collagen scaffold promote non‐cemented hip prosthesis integration , 2011, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[21] A. Nurden. Platelets, inflammation and tissue regeneration , 2011, Thrombosis and Haemostasis.
[22] K. Cherian,et al. “Humanized” Stem Cell Culture Techniques: The Animal Serum Controversy , 2011, Stem cells international.
[23] Thierry Burnouf,et al. Expansion of adipose tissue mesenchymal stromal progenitors in serum‐free medium supplemented with virally inactivated allogeneic human platelet lysate , 2011, Transfusion.
[24] A. Cometa,et al. Ex vivo expansion of mesenchymal stromal cells. , 2011, Best practice & research. Clinical haematology.
[25] P. Bugert,et al. Pathogen Reduction in Blood Products: What’s Behind These Techniques? , 2011, Transfusion Medicine and Hemotherapy.
[26] Karen Bieback,et al. Translating Research into Clinical Scale Manufacturing of Mesenchymal Stromal Cells , 2011, Stem cells international.
[27] M. Pevsner-Fischer,et al. The Origins of Mesenchymal Stromal Cell Heterogeneity , 2011, Stem Cell Reviews and Reports.
[28] M. Andreeff,et al. Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth? , 2010, Stem cells.
[29] Walter Pfaller,et al. Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. , 2011, ALTEX.
[30] C. Centeno,et al. Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. , 2011, Current stem cell research & therapy.
[31] A. Barbero,et al. Fibroblast growth factor 2 and platelet-derived growth factor, but not platelet lysate, induce proliferation-dependent, functional class II major histocompatibility complex antigen in human mesenchymal stem cells. , 2010, Arthritis and rheumatism.
[32] D. Cyranoski. Korean deaths spark inquiry , 2010, Nature.
[33] A. Tuffs. Stem cell treatment in Germany is under scrutiny after child’s death , 2010, BMJ : British Medical Journal.
[34] G. Lucchini,et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] Donald G Phinney,et al. Defining the risks of mesenchymal stromal cell therapy. , 2010, Cytotherapy.
[36] P. Bugert,et al. Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. , 2010, Tissue engineering. Part A.
[37] E. Seifried,et al. Buffy‐coat‐derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? , 2010, Vox sanguinis.
[38] A. Villa,et al. Characterization of platelet lysate cultured mesenchymal stromal cells and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. , 2010, Tissue engineering. Part C, Methods.
[39] O. Korsgren,et al. Photochemical pathogen inactivation of human serum enables its large‐scale application in clinical cell transplantation , 2010, Vox sanguinis.
[40] J. Kramer,et al. Mesenchymal Stem or Stromal Cells: Toward a Better Understanding of Their Biology? , 2010, Transfusion Medicine and Hemotherapy.
[41] W. Marasco,et al. Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. , 2010, Current stem cell research & therapy.
[42] Hélène Rouard,et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. , 2010, Blood.
[43] M. Krampera,et al. Mesenchymal stem cells for clinical application , 2010, Vox sanguinis.
[44] Philippe Bierling,et al. Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. , 2010, Biomaterials.
[45] A. Cometa,et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors , 2009, Haematologica.
[46] D. Strunk,et al. Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal serum-free human stem cell cultures. , 2009, Journal of visualized experiments : JoVE.
[47] D. Gnatenko,et al. The platelet proteome , 2009, Current opinion in hematology.
[48] E. Andreu,et al. Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy , 2009, Transfusion.
[49] D. Strunk,et al. Human Alternatives to Fetal Bovine Serum for the Expansion of Mesenchymal Stromal Cells from Bone Marrow , 2009, Stem cells.
[50] P. Delafontaine,et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. , 2009, Cell stem cell.
[51] A. Kiani,et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium , 2009, Bone Marrow Transplantation.
[52] I. Martin,et al. Platelet lysate as a serum substitute for 2D static and 3D perfusion culture of stromal vascular fraction cells from human adipose tissue. , 2009, Tissue engineering. Part A.
[53] Gerhard Nahler,et al. Committee for Proprietary Medicinal Products (CPMP) , 2009 .
[54] Regina Brunauer,et al. Controversial issue: Is it safe to employ mesenchymal stem cells in cell-based therapies? , 2008, Experimental Gerontology.
[55] E. Seifried,et al. Homing of Mesenchymal Stem Cells , 2008, Transfusion Medicine and Hemotherapy.
[56] T. Tonn,et al. MSC – a Multipotent Stromal Cell in Search of Clinical Application , 2008, Transfusion Medicine and Hemotherapy.
[57] N. Ilić,et al. Points to Consider in Designing Mesenchymal Stem Cell-Based Clinical Trials , 2008, Transfusion Medicine and Hemotherapy.
[58] I. Slaper-Cortenbach. Current Regulations for the Production of Multipotent Mesenchymal Stromal Cells for Clinical Application , 2008, Transfusion Medicine and Hemotherapy.
[59] H. Klingemann,et al. Mesenchymal Stem Cells – Sources and Clinical Applications , 2008, Transfusion Medicine and Hemotherapy.
[60] D. Strunk,et al. Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells , 2008, Transfusion Medicine and Hemotherapy.
[61] Regina Brunauer,et al. Changes of the Functional Capacity of Mesenchymal Stem Cells due to Aging or Age-Associated Disease – Implications for Clinical Applications and Donor Recruitment , 2008, Transfusion Medicine and Hemotherapy.
[62] C. Choong,et al. PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. , 2008, Blood.
[63] H. Northoff,et al. Characteristics of Mesenchymal Stem Cells – New Stars in Regenerative Medicine or Unrecognized Old Fellows in Autologous Regeneration? , 2008, Transfusion Medicine and Hemotherapy.
[64] K. Bieback. Basic Biology of Mesenchymal Stem Cells , 2008, Transfusion Medicine and Hemotherapy.
[65] M. Rojewski,et al. Phenotypic Characterization of Mesenchymal Stem Cells from Various Tissues , 2008, Transfusion Medicine and Hemotherapy.
[66] A. Flake,et al. In vivo Differentiation Potential of Mesenchymal Stem Cells: Prenatal and Postnatal Model Systems , 2008, Transfusion Medicine and Hemotherapy.
[67] A. Ho,et al. The Stromal Activity of Mesenchymal Stromal Cells , 2008, Transfusion Medicine and Hemotherapy.
[68] Annalisa Pasini,et al. Immune Modulation by Mesenchymal Stem Cells , 2008, Transfusion Medicine and Hemotherapy.
[69] G. Dini,et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.
[70] P. Collas,et al. Epigenetic Basis for the Differentiation Potential of Mesenchymal and Embryonic Stem Cells , 2008, Transfusion Medicine and Hemotherapy.
[71] P. Genever,et al. Transcriptional Control of Mesenchymal Stem Cell Differentiation , 2008, Transfusion Medicine and Hemotherapy.
[72] P. Bourin,et al. Mesenchymal Progenitor Cells: Tissue Origin, Isolation And Culture , 2008, Transfusion Medicine and Hemotherapy.
[73] M. Ratajczak,et al. Bone Marrow – Home of Versatile Stem Cells , 2008, Transfusion Medicine and Hemotherapy.
[74] F. Guilak,et al. In vitro Differentiation Potential of Mesenchymal Stem Cells , 2008, Transfusion Medicine and Hemotherapy.
[75] L. Sensébé. Clinical grade production of mesenchymal stem cells. , 2008, Bio-medical materials and engineering.
[76] P. Collas,et al. Genetic and epigenetic instability of human bone marrow mesenchymal stem cells expanded in autologous serum or fetal bovine serum. , 2008, The International journal of developmental biology.
[77] Andrej-Nikolai Spiess,et al. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum‐free medium for transplantation and regenerative medicine , 2007, Journal of cellular physiology.
[78] D. Maynard,et al. Proteomic analysis of platelet α‐granules using mass spectrometry , 2007 .
[79] D. Prockop,et al. “Stemness” Does Not Explain the Repair of Many Tissues by Mesenchymal Stem/Multipotent Stromal Cells (MSCs) , 2007, Clinical pharmacology and therapeutics.
[80] O. Ringdén,et al. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients , 2007, Haematologica.
[81] S. E. Jacobsen,et al. Potential risks of bone marrow cell transplantation into infarcted hearts. , 2007, Blood.
[82] Karl Kashofer,et al. Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells , 2007, Transfusion.
[83] P. Ljungman,et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells , 2007, Leukemia.
[84] H. Klüter,et al. Human AB Serum and Thrombin‐Activated Platelet‐Rich Plasma Are Suitable Alternatives to Fetal Calf Serum for the Expansion of Mesenchymal Stem Cells from Adipose Tissue , 2007, Stem cells.
[85] A. Cometa,et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell‐therapy approaches: Further insights in the search for a fetal calf serum substitute , 2007, Journal of cellular physiology.
[86] E. Lam,et al. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth , 2007, Leukemia.
[87] J. Laine,et al. N‐Glycolylneuraminic Acid Xenoantigen Contamination of Human Embryonic and Mesenchymal Stem Cells Is Substantially Reversible , 2007, Stem cells.
[88] D. Sirbasku,et al. Human platelet lysate contains growth factor activities for established cell lines derived from various tissues of several species , 1980, In Vitro.
[89] J. White,et al. Proteomic analysis of platelet alpha-granules using mass spectrometry. , 2007, Journal of thrombosis and haemostasis : JTH.
[90] I. Rasmusson. Immune modulation by mesenchymal stem cells. , 2006, Experimental cell research.
[91] D. Prockop,et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.
[92] X. Holy,et al. Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell‐based therapy applications , 2005, Journal of cellular physiology.
[93] 室井 一男. What's going on 造血器腫瘍 1)Human mesenchymal stem cells modulate allogeneic immune cell responses. Aggarwal S, Pittenger MF. Blood. 2005;105:1815-22. PMID:15494428. 2)Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Le Blanc K, Rasmusson I, Sun , 2005 .
[94] F. Marini,et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. , 2005, Cytotherapy.
[95] O. Kilian,et al. Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro. , 2004, European journal of medical research.
[96] Moustapha Hassan,et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.
[97] Shu-Ching Hsu,et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[98] Antal Rot,et al. Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions , 2004, Platelets.
[99] G. Sukhikh,et al. Mesenchymal Stem Cells , 2002, Bulletin of Experimental Biology and Medicine.
[100] J. Jonas,et al. Subconjunctival injection of autologous platelet concentrate in the treatment of overfiltrating bleb. , 2003, Journal of glaucoma.
[101] O. Ringdén,et al. Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.
[102] Gerhard Gstraunthaler,et al. Alternatives to the use of fetal bovine serum: serum-free cell culture. , 2003, ALTEX.
[103] H. Klüter,et al. Autologous concentrated platelet-rich plasma (cPRP) for local application in bone regeneration. , 2002, International journal of oral and maxillofacial surgery.
[104] W. Koo,et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. , 2001, Blood.
[105] F. Rendu,et al. The platelet release reaction: granules' constituents, secretion and functions , 2001, Platelets.
[106] S. Gerson,et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] M. Pittenger,et al. Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.
[108] Darwin J. Prockop,et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta , 1999, Nature Medicine.
[109] A I Caplan,et al. The mesengenic process. , 1994, Clinics in plastic surgery.
[110] M. Lindberg,et al. Adipose Tissue , 2018 .
[111] M. Steiner,et al. Platelets as a source of growth-promoting factor(s) for tumor cells. , 1980, Cancer research.
[112] L. Sokoloff,et al. Effect of platelet lysate on growth and sulfated glycosaminoglycan synthesis in articular chondrocyte cultures. , 1980, Arthritis and rheumatism.
[113] N. Kulagina,et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. , 1974, Experimental Hematology.
[114] A. Friedenstein,et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. , 1968, Transplantation.
[115] Reflection paper on stem cell-based medicinal products , 2022 .